COPENHAGEN (Reuters) - Evelyn O’Flynn still has lung cancer. But after going straight on to a new immune system-boosting drug more than a year ago, rather than traditional hard-to-tolerate chemotherapy, she is feeling great. “It’s like a miracle,” said the 72-year-old ex-smoker, who is about to become a great-grandmother.
As a patient being treated with Merck & Co’s immunotherapy drug Keytruda, O’Flynn is one of the lucky ones.
Data presented at the European Society for Medical Oncology (ESMO) congress suggest her early treatment with immunotherapy, as part of a clinical trial in Britain, will become standard for a growing number of patients.
But there is a catch: it doesn’t work for all.
Giving immunotherapy on its own only seems to work better than chemotherapy in previously untreated lung cancer patients who have high levels of a protein called PD-L1, which makes them more receptive to immunotherapy.
From now on, oncologists in Copenhagen have been told, lung cancer patients should be routinely tested for this biomarker.
However, only a quarter to a third of non-small cell lung cancer patients have tumors with at least 50 percent of cells producing PD-L1, leaving the majority unserved and around 70 percent of the market still up for grabs.
The inability to treat everyone with monotherapy using one single drug is a blow for Bristol, which tried to make treatment with its Opdivo drug work across the board, only to fail comprehensively in a major clinical trial.
But it has opened up the field to rivals like Merck, Roche and AstraZeneca, which own what could be among the biggest-selling drugs of all time, and all companies are now racing to find smart ways to combine treatments.
Oncologists poring over immunotherapy trial results at Europe’s biggest cancer meeting have learnt one thing: finding optimal treatments for different patient groups will take more research.
“I think the future of immunotherapy will be defined over the next 10 or 15 years,” said lung cancer specialist Solange Peters from Lausanne University Hospital, one of the organizers of the Copenhagen meeting.
Despite immunotherapy successes and the prospect of a potential market worth up to $40 billion in sales, veteran cancer experts urge caution.
“In oncology, we see these kind of waves from cosmic pessimism to over-optimism, so we have to be cautious,” ESMO President Fortunato Ciardiello said.
Investors, though, were quick to position themselves as shares in Bristol fell 10 percent in early trade on Monday, while Merck hit its highest level since 2001.
By taking the brakes off the immune system and allowing the body’s natural killer cells to home in on tumors, immunotherapy offers a different approach to toxic chemotherapy treatment, which causes collateral damage to healthy tissue.
It is not without side effects but it is a kinder option, which also promises much longer-lasting efficacy.
Bristol, Merck and Roche have U.S. approval for immunotherapies, while Bristol and Merck also sell their drugs in Europe. China, however, has yet to license them.
Lung cancer, the world’s biggest cancer killer with an annual death toll of 1.6 million, will account for by far the largest portion of future prescriptions, although immunotherapy is used additionally in melanoma, Hodgkin lymphoma and cancers of the bladder, kidney, head and neck.
With Merck set to sweep the board in lung cancer monotherapy, doctors are looking to the next phase of the story and there is a growing consensus that combination treatments are the future for remaining patients with lower PD-L1 levels.
“Clearly, the race is on,” said Jean-Charles Soria, a professor of medicine at France’s Institut Gustave Roussy, of the looming battle for dominance in the combination market.
In theory, researchers believe, it should be possible to get more people to respond by adding other drugs to the mix in order to coax the immune system to fight back against cancer cells.
Most attention so far has been on combining two immunotherapies, although this raises questions over cost, with each medicine typically priced at $100,000 to $150,000 a year.
The strategy creates an opportunity for AstraZeneca, which has lagged rivals so far but hopes to jump ahead with a drug cocktail that should report clinical results early next year. Bristol is chasing the same idea, although its double-immunotherapy trial is not expected to have results until 2018.
But the ESMO meeting has also raised the prospect of another approach -- successfully combining immunotherapy and chemotherapy.
A lot of scientists have been sceptical of this idea in the past, and there are still questions over whether patients will have a long-lasting response, but positive data from a mid-stage study at ESMO suggests the concept has real promise. Roche and Merck are both enthusiastic.
Steering a path through all these permutations is going to be a challenge and ESMO’s Ciardiello says the cancer community must await more clinical trial results over the next few years.
“I think we live in great times for rendering cancer a curable disease but it will take time because the more we learn, the more we understand that it is hugely complex,” he told Reuters.
$30-40 BILLION SALES
While nobody yet knows what the “gold standard” treatment regimen is going to be, it is already clear this new generation of drugs is going to be big.
“Every time we come back to the immunotherapy market we are amazed at just how large the opportunity is,” said Leerink analyst Seamus Fernandez, who sees combined annual sales of $30 billion to $40 billion for drugs like Keytruda and Opdivo, as well as rivals from Roche, AstraZeneca and Pfizer.
How the market will ultimately divide between companies is still unclear but Merck certainly emerges from the past weekend in Copenhagen as the main winner.
That underscores a shift in expectations that has been evident since August, when Bristol first revealed its monotherapy trial had failed.
British patient O‘Flynn, whose tumors shrunk dramatically, is just glad she has a chance to try something new.
“My brother had cancer and he had chemotherapy, which was very gruelling. But I haven’t experienced any real side effects, apart from a bit of tiredness.”
Reporting by Ben Hirschler, editing by Peter Millership